Spots Global Cancer Trial Database for magnetic resonance imaging
Every month we try and update this database with for magnetic resonance imaging cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) | NCT05564403 | Recurrent Bilia... Recurrent Dista... Recurrent Gallb... Recurrent Intra... Stage III Dista... Stage III Hilar... Stage III Intra... Stage IV Distal... Stage IV Hilar ... Stage IV Intrah... Unresectable Bi... Unresectable Di... Unresectable Ga... Unresectable In... | Binimetinib Biopsy Biospecimen Col... Bone Scan Computed Tomogr... Echocardiograph... Fluorouracil Leucovorin Calc... Magnetic Resona... Multigated Acqu... Oxaliplatin | 18 Years - | National Cancer Institute (NCI) | |
| Magnetic Resonance Whole Body Diffusion-Weighted Imaging in Finding Bone or Lymph Node Metastasis in Participants With High-Risk Prostate Cancer | NCT03085043 | Prostate Carcin... | Bone Scan Computed Tomogr... Magnetic Resona... Magnetic Resona... | 18 Years - | M.D. Anderson Cancer Center | |
| Predicting Prostate Biopsy Results With Biomarkers and mpMRI. | NCT03730324 | Prostate Cancer | mpMRI Urine and plasm... | 18 Years - 75 Years | Odense University Hospital | |
| Prospective Cohort Study of the Ability of MRI/DTI to Diagnose Prostate Cancer | NCT02934776 | Magnetic Resona... | MRI machine | 18 Years - 90 Years | Rabin Medical Center | |
| Diffusion-weighted MRI to Predict Treatment Response in Stereotactic Radiotherapy of Central Nervous System (CNS) Metastases | NCT04700748 | Radiotherapy Brain Metastase... Sensitivity Radionecrosis | Brain metastase... | 18 Years - | Lund University Hospital | |
| Multiparametric MRI in Men With Prostate Cancer Enrolled in Active Surveillance | NCT03648359 | Prostatic Neopl... | multiparametric... | 18 Years - 75 Years | Herlev Hospital | |
| Differentiation of Malig. & Ben. Solitary Pulm. Nodules & Prediction of Clin. Outcome Using Perfus. Analysis of DCEMRI | NCT00172575 | Lung Neoplasms | 20 Years - | National Taiwan University Hospital | ||
| Particle-based Partial Tumor Irradiation of Unresectable Bulky Tumors | NCT04875871 | Cancer | Particle radiot... Magnetic resona... Computertomogra... Copper-64-Diace... 18-F-FluorDesox... Blood sampling | 18 Years - | EBG MedAustron GmbH | |
| Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal Cancer | NCT06364371 | Predictive Canc... Pathologic Comp... | Medical examina... | 18 Years - 80 Years | Sixth Affiliated Hospital, Sun Yat-sen University | |
| Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2) | NCT06351371 | Malignant Solid... | Biopsy Biospecimen Col... Computed Tomogr... Erdafitinib Magnetic Resona... | 18 Years - | National Cancer Institute (NCI) | |
| Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | NCT01116648 | Fallopian Tube ... Ovarian Endomet... Ovarian High Gr... Ovarian Serous ... Ovarian Serous ... Primary Periton... Triple-Negative... | Biopsy Biospecimen Col... Cediranib Malea... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Olaparib | 18 Years - | National Cancer Institute (NCI) | |
| MR Guidance for Liver and Pancreas | NCT03582189 | Magnetic Resona... | MRI | 18 Years - | University Health Network, Toronto | |
| A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma | NCT04166409 | Low Grade Astro... Low Grade Gliom... Metastatic Low ... Metastatic Low ... | Biospecimen Col... Carboplatin Magnetic Resona... Quality-of-Life... Questionnaire A... Selumetinib Sul... Vincristine Sul... | 2 Years - 21 Years | National Cancer Institute (NCI) | |
| Pilot Study of Pancreatic Cancer Screening | NCT05058846 | Pancreatic Carc... | Biospecimen Col... Magnetic Resona... Magnetic Resona... Endoscopic ultr... Questionnaires | 18 Years - | University of California, San Francisco | |
| Evaluation of the Signa Excite 3.0 T MRI Excite for Detection and Characterization of Liver Lesions | NCT00527891 | Liver Cancer | Signa Excite 3.... | - | M.D. Anderson Cancer Center | |
| Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer | NCT01780701 | Prostate Cancer | Magnetic Resona... | 21 Years - | OHSU Knight Cancer Institute | |
| Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water | NCT01246869 | Brain Cancer | [18F]fluoro-2-d... 1H-1-(3-[18F]-f... [15O]water Magnetic Resona... | 18 Years - | University of Utah | |
| 3T Endorectal Magnetic Resonance Spectroscopic Imaging (MRSI) of Prostate | NCT00429338 | Prostate Cancer | AIR-MRSI PFC-MRSI | 18 Years - | M.D. Anderson Cancer Center | |
| Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRI | NCT04493411 | Multiple Myelom... | WBMRI Positron Emissi... | 18 Years - | University of Texas Southwestern Medical Center | |
| Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis | NCT03317392 | Castration-Resi... Metastatic Pros... Stage IVB Prost... | Biopsy Biospecimen Col... Computed Tomogr... Laboratory Biom... Magnetic Resona... Olaparib Quality-of-Life... Radium Ra 223 D... | 18 Years - | National Cancer Institute (NCI) | |
| Hyperpolarized 13C MRI for Cancer Immunotherapy | NCT05805358 | Gynecologic Can... Cervical Cancer Endometrial Can... Ovarian Cancer | Hyperpolarized ... | 20 Years - | Chang Gung Memorial Hospital | |
| Magnetic Resonance Imaging and Computed Tomography in Patients With Stage I Seminoma of the Testicle | NCT00589537 | Testicular Germ... | questionnaire a... computed tomogr... magnetic resona... quality-of-life... | 16 Years - | National Cancer Institute (NCI) | |
| Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation | NCT05806515 | Prostate Adenoc... Stage IIIB Pros... Stage IIIC Pros... | Biospecimen Col... Carboplatin Chest Radiograp... Computed Tomogr... Magnetic Resona... PSMA PET Scan Surgical Proced... | 18 Years - | SWOG Cancer Research Network | |
| SPIO-enhanced MRI in Oral Cancer for Sentinel Lymph Node Identification | NCT04803331 | Head and Neck S... | SPIO-enhanced M... | 18 Years - | Radboud University Medical Center | |
| Imaging of Prostate Cancer Using Two-dimensional MR Spectroscopy and Diffusion Tensor Imaging | NCT00611065 | Prostate Lesion... | magnetic resona... | 21 Years - 80 Years | University of California, Irvine | |
| Pancreas Cancer Surveillance Using an Abbreviated MRI | NCT04592393 | Pancreas Cancer | Abbreviated PB ... Gene mutation t... Conventional fo... | 50 Years - 75 Years | Seoul National University Hospital | |
| A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma | NCT03880019 | Stage III Uteri... Stage IV Uterin... Uterine Corpus ... | Computed Tomogr... Core Biopsy Magnetic Resona... Olaparib Temozolomide | 18 Years - | National Cancer Institute (NCI) | |
| Clinical Test of the MRgHIFU System on Uterine Fibroids | NCT02283502 | Uterine Fibroid... | MRgHIFU system | 35 Years - 45 Years | Chang Gung Memorial Hospital | |
| Improving Hepatocellular Carcinoma Screening | NCT05828446 | Magnetic Resona... Hepatocellular ... Screening Contrast-enhanc... | MRI | 18 Years - | University of Lausanne Hospitals | |
| Importance of Magnetic Resonance Imaging (MRI) in Treating Breast Cancer | NCT00948285 | Breast Cancer | MRI | 18 Years - 99 Years | Texas Tech University Health Sciences Center | |
| Breast Cancer, Reasoning, and Activity Intervention | NCT04816006 | Breast Cancer Breast Neoplasm... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Cancer-related ... | Aerobic Exercis... Health Educatio... Magnetic Resona... Medical Device ... Gait Assessment | 18 Years - | Mayo Clinic | |
| Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT02446600 | Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Ovarian Clear C... Ovarian Endomet... Ovarian Seromuc... Ovarian Serous ... Ovarian Transit... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Ovari... Recurrent Prima... | Biospecimen Col... Carboplatin Cediranib Malea... Computed Tomogr... Echocardiograph... Gemcitabine Gemcitabine Hyd... Laboratory Biom... Magnetic Resona... Multigated Acqu... Olaparib Paclitaxel Pegylated Lipos... Pharmacological... Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
| Manometry vs Clinical Assessment in the Detection of Trapped Lung in Patients With Suspected Pleural Malignancy | NCT02805062 | Pleural Effusio... | Digital Pleural... Magnetic Resona... | 18 Years - | NHS Greater Glasgow and Clyde | |
| Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations | NCT04548752 | Metastatic Panc... Pancreatic Aden... Stage IV Pancre... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib Pembrolizumab | 18 Years - | National Cancer Institute (NCI) | |
| Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma | NCT03347617 | Glioblastoma | Ferumoxytol Laboratory Biom... Magnetic Resona... Pembrolizumab | 18 Years - | OHSU Knight Cancer Institute | |
| A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) | NCT06401330 | Stage I Kidney ... Stage II Kidney... Stage III Kidne... Stage IV Kidney... | Bone Scan Carboplatin Computed Tomogr... Cyclophosphamid... Dactinomycin Doxorubicin Etoposide Irinotecan Magnetic Resona... Nephrectomy Patient Observa... Positron Emissi... Ultrasound Imag... Vincristine X-Ray Imaging | - 30 Years | Children's Oncology Group | |
| Upright Open MRI for Brain Imaging in Children - a Pilot Study | NCT06257498 | Brain Tumor | MRI scan | 5 Years - 10 Years | Nottingham University Hospitals NHS Trust | |
| Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors | NCT03878095 | Malignant Solid... Refractory Chol... Refractory Mali... | Biopsy Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Ceralasertib Computed Tomogr... Magnetic Resona... Olaparib | 18 Years - | National Cancer Institute (NCI) | |
| 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer | NCT02624518 | Prostate Adenoc... | 68Ga-RM2 Magnetic Resona... Positron Emissi... | 18 Years - | Stanford University | |
| MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy With Exercise Capacity Addendum | NCT01719562 | Cardiac Toxicit... Malignant Neopl... Breast Cancer | Magnetic resona... Physical Activi... Healthy Living Cardiopulmonary... Questionnaire A... | 18 Years - 85 Years | Wake Forest University Health Sciences | |
| Retifanlimab With Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma | NCT06160206 | Recurrent Gliob... Recurrent WHO G... | Bevacizumab Biospecimen Col... Computed Tomogr... Electronic Heal... Hypofractionate... Magnetic Resona... Retifanlimab | 18 Years - | Academic and Community Cancer Research United | |
| pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer | NCT05799144 | Metastatic Orop... Recurrent Oroph... | DNA Vaccine Human Papilloma... Pembrolizumab Computed Tomogr... Magnetic Resona... Magnetic Resona... Biopsy | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer | NCT06307548 | Locally Advance... Recurrent Color... Stage III Color... | Aminolevulinic ... Biospecimen Col... Computed Tomogr... Fluorescence-Gu... Magnetic Resona... Photodynamic Th... Surgical Proced... | 18 Years - | Roswell Park Cancer Institute | |
| National Screening in Denmark With MR Versus Mammography and Ultrasound of Women With BRCA1 or BRCA2 Mutations | NCT00413491 | Breast Cancer | MR mammography MR | 25 Years - 70 Years | Danish Breast Cancer Cooperative Group | |
| Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer | NCT06287775 | Extensive Stage... Stage IV Lung C... | Atezolizumab Biopsy Biospecimen Col... Computed Tomogr... Durvalumab Echocardiograph... Iadademstat Magnetic Resona... Multigated Acqu... | 18 Years - | National Cancer Institute (NCI) | |
| Transfusional Iron Overload Among Leukemia Survivors | NCT01965171 | Acute Lymphocyt... Acute Myeloid L... | 5 Years - | St. Jude Children's Research Hospital | ||
| Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer | NCT03914300 | Differentiated ... Follicular Vari... Poorly Differen... Refractory Diff... Refractory Thyr... Tall Cell Varia... Thyroid Gland F... Thyroid Gland O... Thyroid Gland P... | Biospecimen Col... Cabozantinib S-... Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | NCT04628767 | Renal Pelvis an... | Biopsy Biospecimen Col... Cisplatin Computed Tomogr... Doxorubicin Hyd... Durvalumab Gemcitabine Hyd... Magnetic Resona... Methotrexate Pegfilgrastim Therapeutic Con... Vinblastine Sul... | 18 Years - | National Cancer Institute (NCI) | |
| Gadobutrol Magnevist-controlled Body Study | NCT01050829 | Magnetic Resona... | Gadobutrol (Gad... Gadopentetate D... | 20 Years - | Bayer | |
| Ultrasound Tomography Using SoftVue in Diagnosing Women With Breast Cancer | NCT01698658 | Breast Cancer | ultrasound tomo... magnetic resona... | 18 Years - 89 Years | Barbara Ann Karmanos Cancer Institute | |
| Hyperpolarized 13C MRI for Cancer Immunotherapy | NCT05805358 | Gynecologic Can... Cervical Cancer Endometrial Can... Ovarian Cancer | Hyperpolarized ... | 20 Years - | Chang Gung Memorial Hospital | |
| Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma | NCT06232044 | Recurrent Multi... Refractory Mult... | Iberdomide Belantamab Mafo... Dexamethasone Echocardiograph... Computed Tomogr... Magnetic Resona... Positron Emissi... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Effects of Meditation on Cognitive Function and Quality of Life | NCT02162329 | Breast Cancer | Questionnaires Electroencephal... Magnetic Resona... Meditation Clas... | 35 Years - 65 Years | M.D. Anderson Cancer Center | |
| Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma | NCT05045027 | Glioma Malignant Gliom... Recurrent Gliom... Recurrent Malig... | Biospecimen Col... Diagnostic Imag... Magnetic Resona... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer | NCT01780701 | Prostate Cancer | Magnetic Resona... | 21 Years - | OHSU Knight Cancer Institute | |
| Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer | NCT06129851 | Stage IIC Prost... Stage III Prost... Stage IV Prosta... | Biospecimen Col... Bone Scan Brachytherapy Computed Tomogr... Dual X-ray Abso... External Beam R... Magnetic Resona... PSMA PET Scan Questionnaire A... Relugolix | 18 Years - | University of Kansas Medical Center | |
| Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma | NCT05836571 | Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Undi... | Biopsy Biospecimen Col... Cabozantinib Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation | NCT05610163 | Locally Advance... Stage II Rectal... Stage III Recta... | Capecitabine 5-fluorouracil Leucovorin calc... Irinotecan Oxaliplatin Long Course Che... Computed Tomogr... Magnetic Resona... Sigmoidoscopy biopsy | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery | NCT02590497 | Glioblastoma | Diffusion Weigh... Gadolinium Laboratory Biom... Magnetic Resona... Magnetic Resona... Magnetic Resona... Perfusion Magne... | - | Ohio State University Comprehensive Cancer Center | |
| Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma | NCT05801913 | High Grade B-Ce... Intermediate Gr... Recurrent B-Cel... Refractory B-Ce... | Anti-CD19-CAR C... Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Leukapheresis Lymphodepletion... Magnetic Resona... Multi-peptide C... Positron Emissi... X-Ray Imaging | 18 Years - | City of Hope Medical Center | |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma | NCT05711615 | Metastatic Leio... Metastatic Sarc... Metastatic Soft... Unresectable Le... Unresectable Sa... Unresectable So... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Pegylated Lipos... Peposertib | 18 Years - | National Cancer Institute (NCI) | |
| Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | NCT02496208 | Bladder Small C... Bladder Squamou... Bladder Urothel... Clear Cell Rena... Invasive Bladde... Invasive Bladde... Invasive Sarcom... Kidney Medullar... Malignant Genit... Malignant Solid... Penile Carcinom... Penile Squamous... Renal Cell Carc... Renal Pelvis Ur... Sarcomatoid Ren... Stage III Bladd... Stage III Penil... Stage III Renal... Stage III Renal... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Penile... Stage IV Renal ... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Ureter Urotheli... Urethral Urothe... | Biopsy Biospecimen Col... Cabozantinib S-... Computed Tomogr... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab | 18 Years - | National Cancer Institute (NCI) | |
| MR-Guided Laser Interstitial Thermal Therapy in Treating Patients With Prostate Cancer | NCT01792024 | Stage I Prostat... Stage II Prosta... | Visualase Therm... magnetic resona... | 45 Years - | University of Chicago | |
| Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study | NCT03951142 | Glioblastoma Brain Metastase... | Losartan | 18 Years - | Oslo University Hospital | |
| Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer | NCT03107780 | Glioblastoma Gliosarcoma MGMT-Unmethylat... Recurrent Gliob... | Biospecimen Col... Magnetic Resona... Navtemadlin Radiation Thera... | 18 Years - | National Cancer Institute (NCI) | |
| Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma | NCT03604978 | Grade 2 Meningi... Grade 3 Meningi... Recurrent Menin... | Biospecimen Col... Echocardiograph... Ipilimumab Magnetic Resona... Nivolumab Stereotactic Ra... | 18 Years - | National Cancer Institute (NCI) | |
| Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | NCT04181060 | Advanced Lung N... Metastatic Lung... Recurrent Lung ... Stage IIIB Lung... Stage IV Lung C... | Bevacizumab Biospecimen Col... Computed Tomogr... Echocardiograph... Magnetic Resona... Multigated Acqu... Osimertinib | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment | NCT05432804 | MGMT-Methylated... Recurrent Gliob... Recurrent MGMT-... | Biospecimen Col... Magnetic Resona... Selinexor Temozolomide | 18 Years - | National Cancer Institute (NCI) | |
| MRI and CT Scans to Evaluate Invasive Cervical Cancer Before Treating Patients | NCT00004936 | Cervical Cancer | iodinated contr... computed tomogr... magnetic resona... gadopentetate d... | - | American College of Radiology Imaging Network | |
| Whole Body MRI With DWI for Monitoring Patients Treated for Testicular Cancer Stage II-III | NCT03436901 | Testicular Neop... | MRI with DWI vs... | 18 Years - | Aarhus University Hospital | |
| Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer | NCT02722525 | Cardiovascular ... Prostate Carcin... | Magnetic Resona... Exercise Interv... Perfusion Magne... Exercise Interv... Spectroscopy Laboratory Biom... | - | Ohio State University Comprehensive Cancer Center | |
| Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer | NCT06084845 | Head and Neck S... Hypopharyngeal ... Laryngeal Squam... Oral Cavity Squ... Oropharyngeal S... Stage III Cutan... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Oroph... Stage IV Cutane... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha... | Biospecimen Col... Carboplatin Chest Radiograp... Cisplatin Computed Tomogr... Image Guided Ra... Intensity-Modul... Magnetic Resona... Positron Emissi... Xevinapant | 18 Years - | Eastern Cooperative Oncology Group | |
| Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme | NCT00004262 | Adult Giant Cel... Adult Glioblast... Adult Gliosarco... | conventional su... 3-dimensional c... stereotactic ra... motexafin gadol... magnetic resona... spectroscopy | 18 Years - | National Cancer Institute (NCI) | |
| Diffusion Weighted Magnetic Resonance Imaging for Preoperative Staging in Gastric Adenocarcinoma Patients | NCT01794026 | Gastric Adenoca... | diffusion weigh... | 18 Years - 75 Years | Bezmialem Vakif University | |
| Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer | NCT01810913 | Oropharyngeal p... Stage III Hypop... Stage III Laryn... Stage III Oral ... Stage III Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha... | Atezolizumab Biospecimen Col... Cetuximab Cisplatin Computed Tomogr... Docetaxel Intensity-Modul... Laboratory Biom... Magnetic Resona... Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
| Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study | NCT03793166 | Clear Cell Rena... Metastatic Mali... Metastatic Mali... Metastatic Mali... Metastatic Mali... Sarcomatoid Ren... Stage III Renal... Stage IV Renal ... | Biospecimen Col... Cabozantinib Computed Tomogr... Ipilimumab Magnetic Resona... Nivolumab Quality-of-Life... Questionnaire A... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial | NCT05497804 | ISS Stage III P... Plasma Cell Mye... | Bone Marrow Asp... Carfilzomib Computed Tomogr... Daratumumab Dexamethasone Lenalidomide Magnetic Resona... Positron Emissi... | 18 Years - 80 Years | Mayo Clinic | |
| Virtual Reality for the Improvement of Patients Understanding of Disease and Treatment (MRgRT) | NCT05600556 | Hematopoietic a... Malignant Solid... | Magnetic Resona... Computed Tomogr... Best Practice Questionnaire A... Magnetic Resona... Computed Tomogr... Virtual Technol... Questionnaire A... | 18 Years - | Thomas Jefferson University | |
| Safety Evaluation of Intra-Operative MRI-Based Guidance for Laser Ablation of Epidural Metastasis | NCT02613390 | Spinal Tumor | Magnetic Resona... Questionnaires | 18 Years - | M.D. Anderson Cancer Center | |
| Safety, Ultrasound Conspicuity, and Migration of Twinkling Markers in Patients With Locally Advanced Breast Cancer | NCT05547347 | Anatomic Stage ... Locally Advance... Resectable Brea... | Magnetic Resona... Mammogram Ultrasound Ultrasound-Guid... | 18 Years - | Mayo Clinic |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
